Q-omics provides the consensus-scored KLK6 profile across patient tissues and cancer cell-line models. KLK6 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, KLK6 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, KLK6 RNA expression shows 18,200 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KIRC, and GBM as cancer lineages where KLK6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLK6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLK6 survival associations across molecular data types. KLK6 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLK6 RNA expression–survival associations across cancer types. High KLK6 expression shows unfavorable associations in KIRP, BLCA, LIHC, ACC and PAAD, but favorable associations in ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for KLK6 RNA expression.
This table summarizes KLK6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for KLK6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLK6 shows lower tumor expression in KIRC and KIRP and higher tumor expression in COAD, THCA, LUAD and LUSC. The KIRC box plot shows higher KLK6 RNA expression in normal versus tumor tissue (log2 FC = −3.880, t-test p < 0.001).
This table shows molecular features associated with KLK6 in patient tissues and cancer cell lines. In patient samples, KLK6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KLK6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and OVARY.
